Cancers 2014, 6(2), 1180-1194; doi:10.3390/cancers6021180
Review

Systemic Therapy for Merkel Cell Carcinoma: What’s on the Horizon?

email
Received: 27 February 2014; in revised form: 8 May 2014 / Accepted: 9 May 2014 / Published: 16 May 2014
(This article belongs to the Special Issue Merkel Cell Carcinoma)
View Full-Text   |   Download PDF [561 KB, uploaded 16 May 2014]
Abstract: Merkel cell carcinoma is an aggressive neuroendocrine skin cancer that usually affects elderly patients. Despite being uncommon, incidence has been steadily increasing over the last two decades, likely due to increased awareness, better diagnostic methods and aging of the population. It is currently one of the most lethal cutaneous malignancies, with a five-year overall survival of approximately 50%. With the better understanding of the molecular pathways that lead to the development of Merkel cell carcinoma, there has been an increasing excitement and optimism surrounding novel targeted therapies, in particular to immunotherapy. Some of the concepts surrounding the novel targeted therapies and currently ongoing clinical trials are reviewed here.
Keywords: Merkel cell carcinoma; merkel cell polyomavirus; immunotherapy; targeted therapy
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Rabinowits, G. Systemic Therapy for Merkel Cell Carcinoma: What’s on the Horizon? Cancers 2014, 6, 1180-1194.

AMA Style

Rabinowits G. Systemic Therapy for Merkel Cell Carcinoma: What’s on the Horizon? Cancers. 2014; 6(2):1180-1194.

Chicago/Turabian Style

Rabinowits, Guilherme. 2014. "Systemic Therapy for Merkel Cell Carcinoma: What’s on the Horizon?" Cancers 6, no. 2: 1180-1194.



Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert